

# Karina Dahl Steffensen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6806005/karina-dahl-steffensen-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90  
papers

2,340  
citations

24  
h-index

47  
g-index

100  
ext. papers

2,990  
ext. citations

4.3  
avg, IF

4.88  
L-index

#	Paper	IF	Citations
90	Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. <i>Cell Cycle</i> , <b>2009</b> , 8, 158-66	4.7	398
89	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2403-2415	59.2	334
88	Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells. <i>Oncogene</i> , <b>2008</b> , 27, 225-33	9.2	168
87	Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, 394-403	3.5	135
86	Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. <i>Lancet Oncology</i> , <b>2018</b> , 19, 337-346	21.7	132
85	The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2010</b> , 117, 109-16	4.9	84
84	Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. <i>Journal of Oncology</i> , <b>2011</b> , 2011, 620523	4.5	63
83	The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 820-5	3.5	59
82	The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. <i>Gynecologic Oncology</i> , <b>2010</b> , 118, 167-71	4.9	44
81	Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 1040-7	3.5	40
80	Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2611-8	7.5	37
79	Lessons in Integrating Shared Decision-Making Into Cancer Care. <i>Journal of Oncology Practice</i> , <b>2018</b> , 14, 229-235	3.1	32
78	Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe). <i>Cancer Medicine</i> , <b>2021</b> , 10, 208-219	4.8	31
77	Improved classification of epithelial ovarian cancer: results of 3 danish cohorts. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 1592-600	3.5	30
76	Delta tocotrienol in recurrent ovarian cancer. A phase II trial. <i>Pharmacological Research</i> , <b>2019</b> , 141, 392-396	3.2	29
75	Supraclavicular recurrence after early breast cancer: a curable condition?. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 815-22	4.4	28
74	Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 1842-1849	3.5	27

73	Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 133, 257-65	4.4	27
72	Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 578-84	3.5	27
71	Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3278-82	12.9	26
70	Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1549	5.3	26
69	The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection. <i>International Journal of Gynecological Pathology</i> , <b>2017</b> , 36, 180-189	3.2	25
68	Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. <i>Journal of Ovarian Research</i> , <b>2012</b> , 5, 23	5.5	24
67	Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast. <i>Journal of Histochemistry and Cytochemistry</i> , <b>2011</b> , 59, 750-60	3.4	24
66	Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2013</b> , 139, 995-1003	4.9	23
65	Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression. <i>International Journal of Oncology</i> , <b>2014</b> , 44, 1736-44	4.4	23
64	What Works in Implementing Patient Decision Aids in Routine Clinical Settings? A Rapid Realist Review and Update from the International Patient Decision Aid Standards Collaboration. <i>Medical Decision Making</i> , <b>2021</b> , 41, 907-937	2.5	21
63	The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22, 1474-82	3.5	21
62	Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 168, 551-557	4.4	21
61	Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy. <i>International Journal of Gynecological Cancer</i> , <b>2019</b> ,	3.5	20
60	Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 125, 121-129	7.5	20
59	Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 547-553	6.1	19
58	Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study. <i>International Journal of Gynecological Cancer</i> , <b>2013</b> , 23, 73-80	3.5	19
57	Factors Affecting Patient Decision-making on Surgery for Lumbar Disc Herniation. <i>Spine</i> , <b>2019</b> , 44, 143-149	3.9	17
56	Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma. <i>Melanoma Research</i> , <b>2017</b> , 27, 218-223	3.3	14

55	Implementing shared decision making in Denmark: First steps and future focus areas. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , <b>2017</b> , 123-124, 36-40	1.4	14
54	Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. <i>Cancer Treatment and Research Communications</i> , <b>2018</b> , 14, 7-12	2	14
53	Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy. <i>Laryngoscope</i> , <b>2018</b> , 128, 1493-1500	3.6	14
52	The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab. <i>International Journal of Gynecological Cancer</i> , <b>2016</b> , 26, 1390-8	3.5	14
51	Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. <i>Acta Oncologica</i> , <b>2020</b> , 59, 652-659	3.2	13
50	The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). <i>Gynecologic Oncology</i> , <b>2013</b> , 130, 289-94	4.9	13
49	Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 1500-6	3.5	13
48	Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. <i>Oncology Letters</i> , <b>2016</b> , 11, 3967-3974	2.6	11
47	Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer. <i>Translational Oncology</i> , <b>2019</b> , 12, 968-972	4.9	10
46	Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review. <i>Patient Related Outcome Measures</i> , <b>2019</b> , 10, 117-127	2.9	10
45	What matters in clinical trial decision-making: a systematic review of interviews exploring cancer patients' experiences. <i>Scandinavian Journal of Caring Sciences</i> , <b>2019</b> , 33, 266-278	2.3	9
44	Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up. <i>Pathology Research International</i> , <b>2012</b> , 2012, 851432		9
43	A prospective cohort study of shared decision making in lung cancer diagnostics: Impact of using a patient decision aid. <i>Patient Education and Counseling</i> , <b>2019</b> , 102, 1961-1968	3.1	8
42	How participatory action research changed our view of the challenges of shared decision-making training. <i>Patient Education and Counseling</i> , <b>2018</b> , 101, 639-646	3.1	8
41	Proactive use of PROMs in ovarian cancer survivors: a systematic review. <i>Journal of Ovarian Research</i> , <b>2019</b> , 12, 63	5.5	8
40	Predicting brain metastases of breast cancer based on serum S100B and serum HER2. <i>Oncology Letters</i> , <b>2013</b> , 6, 1265-1270	2.6	8
39	Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling. <i>European Journal of Human Genetics</i> , <b>2016</b> , 24, 1104-11	5.3	7
38	The impact of a patient decision aid on shared decision-making behaviour in oncology care and pulmonary medicine-A field study based on real-life observations. <i>Journal of Evaluation in Clinical Practice</i> , <b>2019</b> , 25, 1121-1130	2.5	6

37	DNA-repair ERCC1 Gene Polymorphisms in Epithelial Ovarian Cancer and Relation to Platinum Resistance and Survival. <i>Journal of Cancer Therapy</i> , <b>2011</b> , 02, 140-147	0.2	6
36	The promise of shared decision making in healthcare. <i>AMS Review</i> , <b>2019</b> , 9, 105-109	3	5
35	Shared decision making when patients consider surgery for lumbar herniated disc: development and test of a patient decision aid. <i>BMC Medical Informatics and Decision Making</i> , <b>2019</b> , 19, 190	3.6	5
34	Quantitative detection of HER2 protein concentration in breast cancer tissue does not increase the number of patients eligible for adjuvant HER2-targeted therapy. <i>Oncology Reports</i> , <b>2013</b> , 29, 1475-82	3.5	5
33	Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer. <i>BMC Cancer</i> , <b>2010</b> , 10, 185	4.8	5
32	Satisfaction with care and adherence to treatment when using patient reported outcomes to individualize follow-up care for women with early breast cancer - a pilot randomized controlled trial. <i>Acta Oncologica</i> , <b>2020</b> , 59, 444-452	3.2	5
31	The impact of shared decision making on time consumption and clinical decisions. A prospective cohort study. <i>Patient Education and Counseling</i> , <b>2021</b> , 104, 1560-1567	3.1	5
30	Preoperative Serum Levels of Epidermal Growth Factor Receptor, HER2, and Vascular Endothelial Growth Factor in Malignant and Benign Ovarian Tumors. <i>Clinical Ovarian Cancer &amp; Other Gynecologic Malignancies</i> , <b>2008</b> , 1, 127-134		4
29	Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. <i>European Journal of Cancer</i> , <b>2021</b> , 149, 128-133	7.5	4
28	Systematic Development of Patient Decision Aids: An Update from the IPDAS Collaboration. <i>Medical Decision Making</i> , <b>2021</b> , 41, 736-754	2.5	4
27	Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. <i>Journal of Ovarian Research</i> , <b>2020</b> , 13, 59	5.5	3
26	The Prognostic Value of Syndecan-1 in Ovarian Cancer Patients with Long-Term Follow up. <i>Clinical Ovarian Cancer &amp; Other Gynecologic Malignancies</i> , <b>2011</b> , 4, 12-18		3
25	VEGF in the Development of Ovarian Malignancy. <i>Clinical Ovarian Cancer &amp; Other Gynecologic Malignancies</i> , <b>2011</b> , 4, 19-25		3
24	Trust-Based Partnerships Are Essential - and Achievable - in Health Care Service. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 1896-1906	6.4	3
23	Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1444-1449	3.5	2
22	Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5540-5540	2.2	2
21	Experiences of involvement in decision-making for patients with breast cancer. A phenomenological-hermeneutical study. <i>European Journal for Person Centered Healthcare</i> , <b>2018</b> , 6, 237	1.3	2
20	Blood natural killer cells during treatment in recurrent ovarian cancer. <i>Acta Oncologica</i> , <b>2020</b> , 59, 1365-1373	3.3	2

19	Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer. <i>Anticancer Research</i> , <b>2020</b> , 40, 5255-5261	2.3	2
18	Providing Balanced Information about Options in Patient Decision Aids: An Update from the International Patient Decision Aid Standards. <i>Medical Decision Making</i> , <b>2021</b> , 41, 780-800	2.5	2
17	Platelet-Derived Growth Factor Gene Polymorphisms in Patients With Ovarian Cancer. <i>Clinical Ovarian and Other Gynecologic Cancer</i> , <b>2012</b> , 5, 10-16		1
16	Tissue immune response in epithelial ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2625-2625		1
15	Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 751-759	3.5	1
14	Association of patient-reported outcomes and ovarian cancer recurrence. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 1248-1259	3.5	1
13	ePRO-based individual follow-up care for women treated for early breast cancer: impact on service use and workflows. <i>Journal of Cancer Survivorship</i> , <b>2021</b> , 15, 485-496	5.1	1
12	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. <i>Gynecologic Oncology</i> , <b>2021</b> , 162, 375-381	4.9	1
11	Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. <i>Clinica Chimica Acta</i> , <b>2021</b> , 522, 152-157	6.2	1
10	Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
9	The challenge of involving old patients with polypharmacy in their medication during hospitalization in a medical emergency department: An ethnographic study.. <i>PLoS ONE</i> , <b>2021</b> , 16, e0261325	3.7	1
8	Practitioners Views on shared decision-making implementation: A qualitative study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259844	3.7	0
7	Shared decision making in high-grade glioma patients-a systematic review. <i>Neuro-Oncology Practice</i> , <b>2020</b> , 7, 589-598	2.2	0
6	The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness. <i>Acta Oncologica</i> , <b>2021</b> , 60, 434-443	3.2	0
5	Shared decision making with breast cancer patients: impact on patient engagement and fear of recurrence. Protocol for a Danish randomized trial in radiotherapy (DBCG RT SDM). <i>Acta Oncologica</i> , <b>2021</b> , 60, 1032-1037	3.2	0
4	A design-led patient campaign development process for disseminating the concept of shared decision making. <i>Design for Health</i> , <b>2019</b> , 3, 305-323	0.8	0
3	HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy. <i>Biomarkers in Medicine</i> , <b>2021</b> , 15, 1309-1317	2.3	0
2	Treosulfan in platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 1045-1051	3.5	

- 1 Shared Decision Making with Acutely Hospitalized, Older Poly-Medicated Patients: A Mixed-Methods Study in an Emergency Department. *International Journal of Environmental Research and Public Health*, **2022**, 19, 6429 4.6